Negative CD19 expression is associated with inferior relapse-free survival in children with RUNX1-RUNX1T1-positive acute myeloid leukaemia: results from the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
Kenichi SakamotoNorio ShibaTakao DeguchiNobutaka KiyokawaYoshiko HashiiAkiko Moriya-SaitoDaisuke TomizawaTakashi TagaSoichi AdachiKeizo HoribeToshihiko ImamuraPublished in: British journal of haematology (2019)
We performed a retrospective analysis of leukaemic surface antigen expression and genomic data from a total of 100 RUNX1-RUNX1T1-positive paediatric acute myeloid leukaemia (AML) patients enrolled in the Japanese Paediatric Leukaemia/Lymphoma Study Group (JPLSG) AML-05 protocol to determine risk factors for relapse. In univariate analysis, the KIT exon 17 mutation (n = 21) and CD19 negativity (n = 59) were significant risk factors for relapse (P = 0·01). In multivariate analysis, CD19 negativity was the sole significant risk factor for relapse (hazard ratio, 3·09; 95% confidence interval, 1·26-7·59; P < 0·01), suggesting that biological differences between CD19-positive and CD19-negative RUNX1-RUNX1T1 AML patients should be investigated.
Keyphrases
- free survival
- acute myeloid leukemia
- transcription factor
- end stage renal disease
- intensive care unit
- ejection fraction
- poor prognosis
- newly diagnosed
- chronic kidney disease
- liver failure
- randomized controlled trial
- bone marrow
- dendritic cells
- gene expression
- diffuse large b cell lymphoma
- machine learning
- acute lymphoblastic leukemia
- prognostic factors
- drug induced
- hepatitis b virus
- electronic health record
- high resolution
- long non coding rna
- artificial intelligence
- big data
- copy number
- data analysis
- high speed